Home › Wilms Tumor › Massachusetts
Wilms Tumor clinical trials in Massachusetts
4 studies for Wilms Tumor are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 29, 2026 · NCT04616560A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
RecruitingPhase 2
Up to age 30 · All sexes · Updated Aug 25, 2026 · NCT04322318Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
- Dana Farber Cancer Institute (Data Collection Only), Boston
RecruitingPhase 2
12 Months · All sexes · Updated May 6, 2026 · NCT05985161From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.